Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, sodium oxybate (Xyrem®) cannot be endorsed for use within NHS Wales for the treatment of cataplexy associated with narcolepsy. |
||
|
||
Medicine details |
||
| Medicine name | sodium oxybate (Xyrem®) | |
| Formulation | 500 mg/ml oral solution | |
| Reference number | 279 | |
| Indication | For the treatment of cataplexy associated with narcolepsy. |
|
| Company | UCB Pharma Ltd | |
| BNF chapter | Central nervous system | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Ratification by Welsh Government | Not available | |
| Date of issue | 02/10/2008 | |